文献速递乳腺癌支持与姑息治疗

术后早期肠内营养对新辅助治疗后乳腺癌患者营养与免疫功能的影响

[The impact of early postoperative enteral nutrition on nutritional status and immune function in breast cancer patients after neoadjuvant therapy].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2026-01-01

该随机对照研究纳入90例接受新辅助治疗的乳腺癌患者,比较术后早期常规饮食联合特殊医学用途肿瘤全营养配方食品与常规饮食的效果。结果显示研究组血清总蛋白、白蛋白及部分免疫指标显著优于对照组,引流管拔管时间更短,提示术后早期肠内营养可改善营养状态、增强免疫功能并促进恢复。

要点

  • 术后早期肠内营养可显著提高新辅助治疗后乳腺癌患者血清总蛋白和白蛋白水平。
  • 研究组CD3⁺、CD8⁺及IgA、IgG、IgM水平显著高于对照组,免疫功能有所改善。
  • 研究组引流管拔管时间显著缩短,切口拆线时间和愈合不良发生率虽较低但无统计学差异。

核心结论

  • 术后早期应用肠内营养支持能有效改善新辅助化疗后乳腺癌患者的营养状态,在一定程度上提高免疫功能,并促进术后恢复。

研究设计与样本

  • 随机对照研究,纳入2024年8月至2025年5月中国医学科学院肿瘤医院接受新辅助治疗的乳腺癌患者90例,随机分为对照组(n=45)和研究组(n=45)。
  • 两组围术期饮食均遵循充足能量、高蛋白、高维生素、低脂肪原则,保证每人每天摄入热量约2 000 kcal;研究组在此基础上口服特殊医学用途肿瘤全营养配方食品。
  • 营养干预均于术后第1天开始,持续至术后第7天。

主要发现

  • 干预后研究组血清总蛋白为(72.42±3.61)g/L,高于对照组的(70.74±3.76)g/L(t=2.040,P=0.045)。
  • 干预后研究组血清白蛋白为(42.96±2.20)g/L,高于对照组的(42.02±1.97)g/L(t=2.027,P=0.046)。
  • 干预后研究组CD3⁺为75.41%±7.72%,高于对照组的69.26%±8.55%(t=2.814,P=0.007);CD8⁺为31.39%±9.43%,高于对照组的26.30%±6.89%(t=2.230,P=0.030)。
  • 研究组IgA、IgG、IgM水平显著高于对照组(均P<0.05)。
  • 研究组引流管拔管时间为(17.05±5.65)d,短于对照组的(19.59±5.54)d(t=-2.029,P=0.046);切口拆线时间和愈合不良发生率低于对照组但差异无统计学意义(均P>0.05)。

临床怎么用

  • 对新辅助治疗后乳腺癌术后患者,可考虑术后第1天启动早期肠内营养,在常规饮食基础上联合口服特殊医学用途肿瘤全营养配方食品并持续至术后第7天。
  • 干预期间需保证每日热量摄入约2 000 kcal,并遵循充足能量、高蛋白、高维生素、低脂肪的饮食原则。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the effects of early postoperative enteral nutrition on nutritional status, immune function, and postoperative recovery in breast cancer patients receiving neoadjuvant therapy. Methods: A total of 90 breast cancer patients who underwent neoadjuvant therapy at the Cancer Hospital, Chinese Academy of Medical Sciences from August 2024 to May 2025 were enrolled. A randomized controlled study design was adopted, and the patients were divided into a control group (n=45) and a study group (n=45) using a random number table method. The perioperative diet for both groups followed the nutritional principles of adequate energy, high protein, high vitamins, and low fat, ensuring a daily caloric intake of approximately 2 000 kcal per person. Patients in the study group additionally received an oral special medical purpose formula food for tumor nutrition. Nutritional intervention in both groups started on the first day after surgery and continued until the seventh day after surgery. Nutritional indicators, immune function parameters, and surgery-related complications were compared between the two groups before and after intervention. Results: Baseline characteristics were balanced between the study group and the control group. There were no statistically significant differences between the two groups in age, body mass index, Nutritional Risk Screening 2002 score, pathological type, or disease stage (all P>0.05). Before the intervention, there were also no statistically significant differences in nutritional indicators (serum total protein, serum albumin) or immune function parameters (T lymphocyte subsets CD3⁺, CD4⁺, CD8⁺, CD4⁺/CD8⁺ratio, immunoglobulins IgA, IgG, IgM) between the two groups (all P>0.05). After the intervention, the nutritional indicator levels in the study group were significantly higher than those in the control group: serum total protein was (72.42±3.61) g/L vs (70.74±3.76) g/L (t=2.040, P=0.045); serum albumin was (42.96±2.20) g/L vs (42.02±1.97) g/L (t=2.027, P=0.046). Additionally, some immune function parameters in the study group were also better than those in the control group: CD3⁺ was 75.41%±7.72% vs 69.26%±8.55% (t=2.814, P=0.007); CD8⁺ was 31.39%±9.43% vs 26.30%±6.89% (t=2.230, P=0.030); the levels of IgA, IgG, and IgM in the study group were also significantly higher than those in the control group (all P<0.05). In terms of postoperative recovery, the drainage tube removal time in the study group was significantly shorter than that in the control group [(17.05±5.65) days vs (19.59±5.54) days; t=-2.029, P=0.046]. The suture removal time and incidence of poor wound healing were also lower in the study group than in the control group, but the differences were not statistically significant (both P>0.05). Conclusion: Early postoperative enteral nutrition support can effectively improve the nutritional status of breast cancer patients after neoadjuvant chemotherapy, enhance immune function to a certain extent, and promote postoperative recovery. 目的: 对于接受新辅助治疗的乳腺癌患者,探讨术后早期肠内营养治疗对其营养状况、免疫功能及术后恢复的影响。 方法: 纳入2024年8月至2025年5月期间就诊于中国医学科学院肿瘤医院接受新辅助治疗的乳腺癌患者90例。采用随机对照研究设计,通过随机数表法将患者分为对照组(n=45)和研究组(n=45)。两组患者围术期饮食均以充足能量、高蛋白、高维生素、低脂肪为营养治疗原则,保证每人每天摄入热量约2 000 kcal,研究组患者在此基础上口服特殊医学用途肿瘤全营养配方食品。两组患者营养干预均于术后第1天开始,持续至术后第7天。比较两组患者干预前后的营养指标、免疫功能指标以及手术相关并发症情况。 结果: 研究组和对照组患者基线特征均衡,两组患者年龄、体质指数、营养风险筛查2002评分、病理类型、分期等差异均无统计学意义(均P>0.05),干预前的营养指标(血清总蛋白、血清白蛋白)、免疫功能指标(T淋巴细胞亚群CD3⁺、CD4⁺、CD8⁺、CD4⁺/CD8⁺比值,免疫球蛋白IgA、IgG、IgM)差异也无统计学意义(均P>0.05)。干预后,研究组患者的营养指标水平显著高于对照组,血清总蛋白分别为(72.42±3.61)和(70.74±3.76)g/L(t=2.040,P=0.045);血清白蛋白分别为(42.96±2.20)和(42.02±1.97)g/L(t=2.027,P=0.046)。同时,研究组患者的部分免疫功能指标也优于对照组,CD3+分别为(75.41±7.72)%和(69.26±8.55)%(t=2.814,P=0.007);CD8+分别为(31.39±9.43)%和(26.30±6.89)%(t=2.230,P=0.030);研究组患者的IgA、IgG、IgM水平也显著高于对照组(均P<0.05)。在术后恢复方面,研究组患者引流管拔管时间显著短于对照组[(17.05±5.65)和(19.59±5.54)d;t=-2.029,P=0.046],切口拆线时间和愈合不良发生率也低于对照组,但差异无统计学意义(均P>0.05)。 结论: 术后早期应用肠内营养支持能有效改善新辅助化疗后乳腺癌患者的营养状态,同时在一定程度上提高免疫功能,促进术后恢复。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Lu W, He X, Zhang K, et al. [The impact of early postoperative enteral nutrition on nutritional status and immune function in breast cancer patients after neoadjuvant therapy]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 42477925. doi:10.3760/cma.j.cn112152-20260113-00028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。